Search Results - "Duriga, Nicole"

Preclinical Development of an anti-5T4 Antibody–Drug Conjugate: Pharmacokinetics in Mice, Rats, and NHP and Tumor/Tissue Distribution in Mice by Leal, Mauricio, Wentland, JoAnn, Han, Xiaogang, Zhang, Yanhua, Rago, Brian, Duriga, Nicole, Spriggs, Franklin, Kadar, Eugene, Song, Wei, McNally, James, Shakey, Quazi, Lorello, Leslie, Lucas, Judy, Sapra, Puja

“…The pharmacokinetics of an antibody (huA1)–drug (auristatin microtubule disrupting MMAF) conjugate, targeting 5T4-expressing cells, were characterized during…”
Get full text

Preclinical Pharmacokinetics, Pharmacodynamics, Tissue Distribution, and Interspecies Scaling of Recombinant Human Coagulation Factor Xa I16L by Parng, Chuenlei, Markiewicz, Victoria, Chen, Jianqing, Leary, Beth, Duriga, Nicole, Dyleski, Lisa, Caiazzo, Teresa, Bolt, Michael, Joyce, Alison, Gorovits, Boris, Pittman, Debra D, Webster, Robert

“…FXa is a recombinant human FXa variant which is currently being evaluated in the clinic for treating intracerebral hemorrhage. The aim of our studies is to…”
Get more information

Bioanalytical platform comparison using a generic human IgG PK assay format by Leary, Beth A., Lawrence-Henderson, Rosemary, Mallozzi, Carolyn, Fernandez Ocaña, Mireia, Duriga, Nicole, O’Hara, Denise M., Kavosi, Mania, Qu, Qiang, Joyce, Alison P.

“…A comparison of four different ligand-binding assay technology platforms (ELISA, Meso Scale Discovery®, Gyros® and AlphaLISA®) was conducted using quantitative…”
Get full text

Resolution of matrix interference: quantitative and quasi-quantitative ligand-binding assays case studies by Spriggs, Franklin P, Duriga, Nicole, Rathi, Alok, Qu, Qiang

“…Matrix effects pose a constant challenge in developing robust ligand-binding assays to be validated for use in nonclinical and clinical study support. When…”
Get full text